In the present study, combinational therapy of metapristone and sorafenib delivered by CXCR4-targeted PLGA-PEG NPs, was performed to synergistically inhibit HCC progression through reducing CXCR4 expression by metapristone and blocking interaction of SDF-1/CXCR4 by LFC131 peptide (Fig. 7b). This evidence concerns the gene CXCL12 and hepatocellular carcinoma.